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Inhibition of renin with an active site inhibitor, aliskiren,
lowers blood pressure (BP) in diabetic patients. Here, we
studied the time course of the antihypertensive and
antiproteinuric effect of renin inhibition in 15 patients with
type 2 diabetes and elevated urinary albumin/creatinine
ratios (UACRs) to check whether aliskiren can decrease
proteinuria. After a 4-week washout of previous medications,
patients received aliskiren and furosemide daily for 28 days
followed by a 4-week withdrawal period. Twenty-four-hour
BPs were measured at baseline throughout treatment and
withdrawal periods. The UACR was significantly reduced after
2–4 days of treatment with another significant reduction after
28 days. Systolic blood pressure (SBP) was significantly lower
after 7 days with no further reduction after 28 days. The BP
returned toward baseline 3 days after withdrawal, whereas
the UACR was still significantly reduced compared with
baseline 12 days after withdrawal. Our study shows that
aliskiren reduced 24h SBP, and this was associated with a
reduction in albuminuria in type 2 diabetic patients.
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Treatment of diabetic nephropathy relies on blockade of the
renin–angiotensin–aldosterone system (RAAS).1 Angiotensin
II receptor blockers (ARBs) like irbesartan, losartan, and
valsartan are standard therapy in patients with type 2
diabetes and micro- or macroalbuminuria after results of
landmark trials.2–5 In smaller studies, improved ways of
blocking the RAAS has been investigated, with albuminuria
reduction as the main end point. Blockade of the aldosterone
receptor,6 dual-blockade using both angiotensin-converting
enzyme (ACE) inhibitors and ARBs,7,8 and ultrahigh doses of
ARBs9 have shown additional effect on albuminuria but has
not yet demonstrated prevention of end-stage renal disease or
death in diabetes.
Large trials have shown that albuminuria is a marker for
renal and cardiovascular risk in patients with type 2 diabetes
and diabetic nephropathy.10 Lowering albuminuria is asso-
ciated with a reduced risk for renal and cardiovascular end
points.11 Thus any residual albuminuria in these patients calls
for more effective RAAS blockade.
Renin inhibition is a new option to block the RAAS at
the first rate-limiting step. Renin inhibition with aliskiren
lowers blood pressure (BP) in hypertensive patients with
or without type 2 diabetes,12,13 but it is not known whether
this treatment can decrease albuminuria. Renin inhibition
with remikiren leads to albuminuria reduction in nondiabetic
hypertensive patients.14
Preliminary data suggest a more complete suppression
of the intra-renal RAAS with direct renin inhibition as
compared with ARBs and ACE inhibitors.15 In contrast to
ACE inhibitors/ARBs, all components of the RAAS are
suppressed except plasma renin concentration.16
The aim of this study was to investigate the time course of
the antihypertensive and the antiproteinuric effects of direct
renin inhibition by aliskiren in patients with type 2 diabetes
and micro- or macroalbuminuria. We also investigated the
effect on RAAS components and on biomarkers of cardio-
vascular risk.
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RESULTS
A total of 37 patients gave informed consent, 16 of these
were screen failures mainly due to BP above the safety limit
or low urinary albumin/creatinine ratio (UACR) levels. After
4 weeks washout (Figure 1), 21 patients were considered
eligible for dosing at baseline. Six of these were early dropouts
(one withdrew consent, two had normoalbuminuria at
baseline and three were excluded following rise in BP shortly
after first dose (days 3, 3, and 7). Two patients who were
excluded during the post-treatment washout were included
in the analysis, as they went through the treatment period
with all measurements. In accordance with this, BP at
baseline was higher in the 8 patients who dropped out of
the study compared with the 13 patients who completed the
study (Table 1). As the dropouts came at an early point in the
treatment phase, no relation to study drug was suspected.
Thirteen patients completed all phases of the study.
Clinical data of the 21 eligible patients, the 15 included in the
analysis, and the 13 patients who completed all study periods
are given in Table 1.
24h BP
At baseline, mean (s.d.) 24 h BP was 143/75 (12.8/9.6) mm Hg,
daytime BP was 147/77 (12.3/10.0) mm Hg, and nighttime BP
was 130/68 (14.3/10.0) mm Hg. The mean 24 h systolic BP
(SBP) was significantly reduced with 6–8 mm Hg on days 7
(P¼ 0.037), 14 (P¼ 0.006), and 28 (P¼ 0.035) compared with
baseline (Figure 2). Three days after the end of treatment, SBP
was still significantly lower compared with baseline (P¼ 0.016),
but returned toward baseline at day 35. Daytime SBP changes
were similar; nighttime SBP did not change significantly.
Twenty-four-hour mean diastolic BP (DBP), daytime
DBP, and nighttime DBP were not significantly different
from baseline during treatment and post-treatment, but
baseline levels were low (75 mm Hg) (Figure 2).
Urinary albumin/creatinine ratio
Baseline UACR was 173 (39–1725) mg g1 (median and
range). Aliskiren treatment was associated with a significant
decrease in albuminuria throughout the treatment period
(Figure 2a). UACR values decreased progressively compared
with baseline with a 17% reduction on days 2–4 (P¼ 0.04), a
31% reduction on days 8–10 (Po0.001), and a maximum
reduction of 44% at end of the treatment (days 26–28)
(Po0.001). Five of the 15 patients had 450% reduction in
albuminuria at the end of treatment compared with baseline,
11 of the 15 had 425% reduction, and 13 had 410%
reduction (data not shown). During post-treatment washout,
UACR remained significantly below baseline for 12 days (days
29–40). Urinary sodium excretion did not differ significantly
during the study (data not shown). There was no significant
correlation between the relative change from baseline in
UACR and in 24 h SBP (r¼ 0.298, P¼ 0.347).
The time course of the changes in UACR and 24 h BP were
not concordant, as significant changes in UACR happened
earlier (days 2–4) than changes in 24 h BP (day 7). UACR was
further reduced during the treatment period, whereas the
24 h BP did not change further after day 7 (Figure 1).
Estimated glomerular filtration rate
Estimated glomerular filtration rate at baseline was 75.5 ml
per min per 1.73 m2. At the end of treatment, this had
decreased by 6 ml per min per 1.73 m2 and returned toward
baseline during post-treatment washout. None of these
changes were statistically significant.
28-day washout 28-day treatment 28-day washout
FurosemideFurosemide Aliskiren 300 mg o.d. 
Furosemide
Day  –28 Day 1 Day 28 Day 56
UACR: morning spot urine on day 1 – 56
24 h BP: days 1, 3, 7, 14, 28, 31, 35, 42, 56
Baseline End of treatment
Figure 1 | Study timeline. Four weeks washout, 4 weeks of
treatment, followed by 4 weeks withdrawal.
Table 1 | Demographics of patients with type 2 diabetes, hypertension, and albuminuria
Demographics All randomized patients (n=21) Patients completing active treatment (n=15) Patients completing study (n=13)
Age 64.6 (7.3) 63.5 (10.3) 65.8 (5.9)
Height (cm) 173.1 (5.5) 174.3 (5.1) 173.7 (5.0)
Weight (kg) 97.1 (17.7) 100.0 (16.1) 98.8 (16.1)
Male gender, n (%) 18 (86%) 13 (87%) 12 (92%)
Caucasian, n (%) 21 (100%) 15 (100%) 13 (100%)
HbA1c 8.0 (1.3) 7.9 (1.2) 8.0 (1.2)
Plasma creatinine (mmol l1) 97 (32) 97 (34) 94 (31)
UACR (mgg1)a 158 (18–5060) 173 (39–1725) 158 (39–1069)
24 hour BP (mmHg) 146/76 (15/10) 143/75 (13/10) 139/72 (9/6)
Mean daytime BP (mmHg) 144/77 (19/13) 147/77 (12/10) 141/75 (17/10)
Mean nighttime BP (mmHg) 133/71 (18/13) 130/68 (14/10) 128/67 (14/10)
BP, blood pressure; UACR, urinary albumin/creatinine ratio.
All values are mean and (s.d.) except UACR values.
aMedian (range).
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RAAS components
Levels of RAAS components are given in Table 2. Aliskiren
treatment was associated with significant increases in
prorenin (30% on day 28, Po0.001 vs baseline) and renin
concentration (404% from baseline on day 7, Po0.001) and
decreases in plasma renin activity (PRA) (67–77%, Po0.001
vs baseline), angiotensin I (Ang I), and angiotensin II (Ang
II) (Figure 1d). One week after withdrawal, prorenin levels
were not significantly different from baseline. Comparable
reductions in Ang I levels were observed on days 7 (80%
reduction), 14 (80% reduction), and 28 (81% reduction)
(Figure 1d). The reduction in Ang II levels on day 7 (58%)
were slightly greater than on day 28 (43%) (P¼ 0.044 for the
comparison of the 2 days).
During post-treatment washout, renin concentrations
decreased, but remained elevated compared with baseline
by 73% (Po0.001) on day 54. There was a significant
correlation between change in UACR and change in renin
concentration (Spearman’s r, P¼ 0.033). After withdrawal,
PRA remained significantly reduced from baseline on day 35
(49% reduction, P¼ 0.010). PRA on day 54 was not
significantly different from baseline.
After withdrawal, Ang I and Ang II levels remained
significantly suppressed. Ang I levels were still reduced 42%
at day 54 (Po0.001), and Ang II levels were reduced by 34%
(P¼ 0.010) at day 35 but returned to baseline level at day 54.
Angiotensinogen was measured in 13 of the 15 patients, and
ACE activity was measured in 14 of the 15 patients.
No significant changes were found (Table 2).
The changes in mean levels of aldosterone were not
significant (Table 2).
Biomarkers
We also measured the impact of direct renin inhibition on
biomarkers of cardiovascular risk. Levels are shown in
Table 2. There were no significant changes in levels of any
of the biomarkers during the study compared with baseline.
Safety
A total of four (26.7%) patients experienced eight adverse
events during the study. The most common adverse event,
occurring in 2 of 15 (13.3%) patients, was mild hypo-
glycemia, occurring during post-treatment (days 35 and 38).
One patient discontinued the study due to hypertension
on day 42 (post-treatment washout) following sitting and
standing BP measurements of 170/80 and 177/87 mm Hg,
respectively. No event of hyperkalemia (plasma potassium
45.0 mmol l1) was recorded during the study.
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Figure 2 | Effect of renin inhibition on UACR, 24 h BP and RAAS components. (a) UACR (mgg1) (geometric means) in 15 type 2
diabetic patients with micro- or macroalbuminuria treated with aliskiren for 28 days followed by 28 days washout. (b) 24 h SBP (s.e.m) in
15 type 2 diabetic patients with micro- or macroalbuminuria treated with aliskiren for 28 days followed by 28 days washout. (c) 24 h DBP
(s.e.m) in 15 type 2 diabetic patients with micro- or macroalbuminuria treated with aliskiren for 28 days followed by 28 days washout.
(d) Plasma renin activity, Ang I and Ang II (ratio of geometric means relative to baseline) in 15 type 2 diabetic patients with micro- or
macroalbuminuria treated with aliskiren for 28 days followed by 28 days washout.
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DISCUSSION
We found that treatment with aliskiren 300 mg once daily was
associated with a decrease in UACR by 17% after 2–4 days
with a 44% reduction after 28 days of treatment. Twenty-
four-hour SBP decreased 6 mm Hg by day 7 and 8 mm Hg
by day 14. The time course of changes in UACR and SBP
was not concordant. After withdrawal, UACR remained
significantly below baseline for 12 days, whereas SBP was
significantly below baseline for only 3 days. There was no
significant correlation between change in UACR and change
in SBP.
In a time-course study with losartan 100 mg daily in
type 1 diabetes and diabetic nephropathy, Andersen et al.17
found a 25% reduction in UACR on day 4, from a baseline
level higher than that in our study (676 mg g1) and with a
larger reduction in SBP (12 mm Hg). The authors did not find
any separation between changes in BP and changes in UACR.
The UACR reduction in our study is in the same order
of magnitude as with other RAAS inhibitors in similar
populations with type 2 diabetes. In the IRMA 2 study,
300 mg of irbesartan once daily reduced urinary albumin
excretion by 38%.2 In 102 hypertensive Chinese patients
with type 2 diabetes, Chan et al.18 demonstrated an overall
56% reduction in proteinuria after 1 year of treatment with
enalapril 40 mg day1. Aliskiren treatment on top of conven-
tional treatment, including losartan 100 mg once daily, in
type 2 diabetes and nephropathy has recently shown a 20%
albuminuria reduction in patients with more severe disease
than in our study.19 This study also demonstrated that the
maximal albuminuria-lowering effect occurred after 1 month
of treatment.
In our study, we used the dose of aliskiren developed
for optimal treatment of arterial hypertension. The optimal
dose for albuminuria reduction is not necessarily the same,
as is the case with irbesartan, where higher doses may be
required for optimal renoprotection.9 This will need further
investigation.
Renin inhibition has shown renoprotective potential in
animal studies. In diabetic rats with renal injury, aliskiren
treatment attenuated SBP, albuminuria, and glomerulosclero-
tic index compared with diabetic controls. Furthermore,
tubular interstitial fibrosis was more reduced compared with
diabetic rats treated with the ACE inhibitor, perindopril.20
The mechanism by which RAAS blockade alters the
filtration of proteins in diabetic nephropathy is not fully
understood. Trevisan and others21 have proposed that
reductions in intraglomerular pressure with RAAS blockade
lowers albuminuria. Previous studies of the permeability of
the glomerular membrane indicate an improved size selecti-
vity with RAAS blockade.22,23 Treatment with enalapril
improved charge selectivity by attenuating loss of heparin
sulfate from the glomerular basement membrane in diabetic
rats.24 In recent studies, the role of nephrin, a protein present
in the slit diaphragm of the podocyte, has been investigated.
It appears from human studies25 that nephrin levels are
inversely associated with the degree of proteinuria, and that
RAAS blockade improves nephrin expression to control
levels. The effect of aliskiren treatment on the mentioned
pathways remains to be elucidated.
The effect of aliskiren treatment on ambulatory BP has
been assessed in a few randomized studies. In nondiabetic
patients with mild-to-moderate hypertension, a reduction
in daytime ambulatory SBP was found. The authors reported
a placebo-controlled reduction, compared with baseline, of
11 mm Hg after 4 weeks with 300 mg aliskiren once daily as
the only antihypertensive treatment.12 Other aliskiren studies
have found similar reductions in office SBP.13 In our study,
24 h BP reductions are smaller than in the above-mentioned
Table 2 | RAAS components and biomarker levels at baseline, at the end of treatment (day 28), and after post-treatment
washout (day 54), n=15
Baseline End of treatment End of study
Angiotensinogen (nmol l1) 1032 (210) 1072 (211) 995 (157) NS
Prorenin (ng l1) 393 (282) 499 (320) 407 (265) Po0.001a
Renin (ng l1) 26 (20) 193 (287) 89 (152) Po0.001a
PRA (pmol AngI per ml per h) 4.1 (3.1) 1.3 (0.92) 4.2 (1.5) Po0.001a
Ang I (pmol l1) 39.5 (23.4) 7.4 (3.7) 33.0 (51.4) Po0.001a
ACE activity (U) 40.1 (8.1) 41.5 (8.8) 40.2 (11.2) NS
Ang II (pmol l1) 15.1 (11.1) 8.7 (7.4) 14.4 (8.7) P=0.044a
Aldosterone (ng l1) 81.8 (45.8) 72.5 (37.4) 85.5 (37.7) NS
hs-CRP (mg l1) 3.33 (3.47) 3.69 (3.87) 4.18 (5.29) NS
vWF (%) 151 (52) 144 (45) 144 (48) NS
sVCAM-1 (mg l1) 886 (303) 956 (471) 913 (342) NS
sICAM-1 (mg l1) 637 (294) 619 (263) 618 (253) NS
PAI-1 (mg l1) 98 (49) 135 (87) 131 (99) NS
NT-proBNP (pmol l1) 338 (73) 308 (60) 318 (59) NS
ADMA (mmol l1) 0.49 (0.05) 0.49 (0.06) 0.50 (0.06) NS
ACE, angiotensin-converting enzyme; ADMA, asymmetrical dimethyl arginine; Ang I, angiotensin I; Ang II, angiotensin II; hs-CRP, high-sensitivity C-reactive protein;
NT-proBNP, N-terminal-pro brain natriuretic peptide; PAI-1, plasminogen activator inhibitor-1; PRA, plasma renin activity; sICAM-1, serum-soluble intercellular adhesion
molecule-1; sVCAM-1, serum-soluble vascular adhesion molecule-1; vWF, von Willebrand factor.
Values are mean (s.d.).
aEnd of treatment (day 28) compared with baseline.
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studies, probably because baseline 24 h SBP was only slightly
elevated.
Aliskiren inhibits renin from converting angiotensinogen
to Ang I by binding to the active site; however, it can also
bind to prorenin. Recently, a (pro)renin receptor has been
discovered,26 through which prorenin may exert effects in an
angiotensin-independent manner.27 Whether prorenin
bound to aliskiren also exerts an effect via this receptor is
unknown, but obviously this could have implications for
the angiotensin-independent (pro)renin receptor pathways in
the kidney that are potentially deleterious.28,29 If receptor
binding of prorenin/renin contributes to the pathophysiology
of diabetic nephropathy, and if renin inhibition interrupts
this sequence, this could be a new pathway of action in RAAS
blockade.
The reduction in PRA is accompanied by a reactive increase
in renin and prorenin, which is of interest in relationship with
the potential activation of the (pro)renin receptor under these
conditions. On the one hand, the receptor may be down-
regulated by such high renin/prorenin levels,30 whereas on the
other hand, the activation of the receptor may be disturbed
due to aliskiren-induced conformational changes in the renin/
prorenin molecule. Further research is needed to establish the
percentage of plasma renin and prorenin that is bound to
aliskiren. Such research should also take into consideration
the fact that high prorenin levels are associated with the
development of diabetic microangiopathy.31 Aliskiren treat-
ment had no effect on the markers of endothelial dysfunction
and inflammation, that is, biomarkers of cardiovascular risk.
This is in contrast to irbesartan treatment, which lowers
markers of inflammation.32 An effect cannot be excluded due
to profiles of patients with relatively low cardiovascular risk,
short-term treatment, or lack of power. In general, aliskiren
was well tolerated, and the adverse events reported were mild
and similar to other aliskiren studies.
The study design was primarily intended to investigate the
time course of aliskiren treatment, and the results imply that
direct renin inhibition may be a new treatment of diabetic
kidney disease. As this was an open trial, these results will
need confirmation, also given the small number of partici-
pants and the number of dropouts (although not considered
related to study drug). The results are thus preliminary, but
support the concept that RAAS blockade with direct renin
inhibition can decrease albuminuria. Further double-blind,
randomized trials of efficacy and safety of aliskiren in diabetic
nephropathy are needed19 before aliskiren can be added
to currently recommended renoprotective treatments. All
patients in this study were Caucasians, which limits inter-
pretation of the results concerning race differences. The
lasting effect on the clinical variables and the RAAS
components after withdrawal could be of clinical value, as
drug holidays will have less impact on UACR and BP levels.
In conclusion, aliskiren 300 mg once daily was associated
with a reduction in UACR and 24 h SBP in patients with type
2 diabetes and albuminuria. This is a small exploratory study
that needs confirmation in a larger trial.
MATERIALS AND METHODS
This open single-centre trial enrolled patients with type 2 diabetes
(WHO criteria), hypertension (X135 or X85 mm Hg) and micro-
or macroalbuminuria (UACR 430 mg g1 o2000 mg g1). UACR
was measured at baseline after 4 weeks of washout, with no RAAS
blocking treatments allowed. Patients were between 30 and 80 years
with an estimated glomerular filtration rate X40 ml per min per
1.73 m2. Exclusion criteria included a safety limit for BP at any time
in the study (4170/105 mm Hg), heart failure (NYHA Class II–IV),
HbA1c 411%, and nondiabetic renal disease.
The study was approved by the local ethics committee and was
conducted according to the Declaration of Helsinki Principles and
Good Clinical Practice. The study was conducted at the Steno
Diabetes Center, Gentofte, Denmark.
Washout. After giving informed consent, patients were
screened and underwent a 4 week washout, with all antihypertensive
medications paused (Figure 1). During washout and throughout
the study, patients were given long-acting furosemide in a stable
dose to prevent BP elevation and fluid retention and to minimize
the interference from changes in dietary sodium intake. To
detect important changes in BP, patients were handed automatic
BP devices (U&A 779, A&D Instruments Ltd., Abingdon, UK)
for measurements twice daily, to ensure that BP did not exceed
170/105 mm Hg. These measurements were not used in any efficacy
evaluation. Estimated glomerular filtration rate was calculated using
the revised MDRD formula33 at baseline, at the end of treatment
and 7 and 26 days after the end of treatment.
Treatment. After washout, patients attended a baseline visit
for ECG, blood sampling, physical examination, and 24 h ambula-
tory BP. Patients then received 300 mg aliskiren once daily and
furosemide in a stable dose for 28 days.
Post-treatment. To assess a possible rebound effect, the treat-
ment was followed by a 28-day washout. All patients continued
furosemide in the same dose as during treatment.
Outcome measurements
Twenty-four-hour BP was measured at baseline, during treatment
(days 3, 7, 14, and 28) and during post-treatment washout (days 31,
35, 42, and 54) using a 24 h auscultatory BP device (Takeda
TM2421, version 7) (A&D Medical, Tokyo, Japan). BP was measured
every 15 min during the day (0700 to 2300 hours) and every 30 min
during the night (2300 to 0700 hours). Values were averaged for
each hour before calculating mean day, night, and 24 h values.
Urinary albumin/creatinine ratio
Morning urine samples were collected to measure UACR at
screening, at baseline, during the treatment period (daily from days
1 to 28), and during post-treatment washout (days 29–54).
Twenty-four-hour urine collections were performed at baseline,
during treatment (day 3), and during post-treatment washout (day
35) to measure albumin, creatinine, sodium, and urea. This was to
detect fluctuations in sodium excretion, which could influence the
effect of RAAS blockade.
Laboratory methods
Urinary albumin and creatinine concentrations were determined in
morning urine samples on a turbidimetric Hitachi 912 System
(Roche Diagnostics, Mannheim, Germany).
Blood samples for prorenin, PRA, renin concentration, angio-
tensinogen, Ang I, ACE activity, Ang II, and aldosterone levels were
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taken after 30 min of supine rest, and after centrifugation the plasma
was frozen (801C). These parameters were measured at baseline,
during treatment (days 7, 14, and 28) and during post-treatment
washout (days 35 and 54).
Renin concentration was measured with an immunoradiometric
kit (Renin III, CisBio, Gif-sur-Yvette, France). Total renin concentra-
tion was determined simultaneously with the same kit, after previous
changing of the prorenin conformation into a form recognizable by
the IRMA antibodies by incubating for 48 h at 41C with aliskiren.34
Subtraction of renin concentration from total renin concentration gave
the estimated prorenin concentration. PRA was measured by in-house
radioimmunoassay of Ang I formed during incubation of plasma for
1 h at 371C. No inhibitors were present during the incubation, but
instead the antibody-trapping method was used.35
Plasma angiotensinogen concentration was determined based on
conversion of angiotensinogen to Ang I by exogenous human renin
using antibody trapping36 as modified by Millar et al.37
Plasma Ang I and Ang II were measured using in-house radio-
immunoassays and ethanol extraction of plasma samples. Anti-
bodies were raised in rabbits and calibrators were purchased from
NIBSC (Hertfordshire, UK). ACE activity was determined using
a commercial radioenzymatic assay (ACE direct, Bu¨hlmann-
Laboratories AG, Scho¨nenbuch, Switzerland).
Aldosterone was measured with a radioimmunoassay kit (Coat-
A-Count, Diagnostic Products Corporation, Los Angeles, CA, USA).
Biomarkers of inflammation, endothelial dysfunction, and cardio-
vascular risk were measured: high-sensitivity C-reactive protein
(EIA, DAKO A/S, Glostrup, Denmark); plasma von Willebrand factor
(RIA, Precision BioLogic Inc., Dartmouth, Canada); serum-soluble
vascular adhesion molecule-1, and serum-soluble intercellular adhe-
sion molecule-1 (EIA, Diaclone, Besanc¸on, France); plasma plasmino-
gen activator inhibitor-1 (HYPHEN BioMed kit, Andresy, France);
serum N-terminal-pro brain natriuretic peptide (EIA, Biomedica kit,
Wien, Austria); and plasma asymmetrical dimethyl arginine (high-
performance liquid chromatography).38 Biomarkers were measured at
the same study days as the RAAS components.
Statistical analysis
The log-transformed values of UACR (days 1–54) were analyzed
using a mixed model where the term ‘patient’ was fitted as a random
effect and the term ‘day’ was fitted as a fixed effect.
The estimated daily average with its standard error was reported.
Days 2–52 were divided into intervals of three consecutive days (that
is, days 2–4, days 5–7, y, days 50–52), and days 53–54 were divided
into an interval of 2 consecutive days. Each 2- or 3-day interval
average was compared with the baseline (day 1). Point estimates and
corresponding 95% confidence intervals were reported.
For BP data, the average values of the 24 h SBP or DBP were
analyzed using the same mixed model. Trends of UACR over time
and BP over time were explored using graphical methods. All tests
were two sided and used the 5% level of significance.
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